IMB Dx, Inc. (KOSDAQ: 461030)

Market Cap	145.08B
Revenue	n/a
Net Income	n/a
Shares Out	14.02M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,591
Average Volume	84,651
Open	10,200
Previous Close	10,270
Day's Range	10,170 - 10,630
52-Week Range	8,430 - 40,550
Beta	n/a
RSI	42.11
Earnings Date	n/a

About IMB Dx

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer ea...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 461030